Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer, June 2019

Free Subscription


Abstracts

Retrieve all available abstracts of the following 152 articles:
HTML format


 

Single Articles

  1. YU EY, Wesselius A, van Osch F, Stern MC, et al
    The association between coffee consumption and bladder cancer in the bladder cancer epidemiology and nutritional determinants (BLEND) international pooled study.
    Cancer Causes Control. 2019 May 30. pii: 10.1007/s10552-019-01191.
    Abstract    

    Abstract available

  2. TIAN H, Wang X, Lu J, Tian W, et al
    MicroRNA-621 inhibits cell proliferation and metastasis in bladder cancer by suppressing Wnt/beta-catenin signaling.
    Chem Biol Interact. 2019 May 27. pii: S0009-2797(19)30587.
    Abstract    

    Abstract available

  3. JAHNSON S, Gardmark T, Hosseini A, Jerlstrom T, et al
    Management and outcome of TaG3 tumours of the urinary bladder in the nationwide, population-based bladder cancer database Sweden (BladderBaSe).
    Scand J Urol. 2019 May 30:1-6. doi: 10.1080/21681805.2019.1621377.
    Abstract    

    Abstract available

  4. POLI G, Egidi MG, Cochetti G, Brancorsini S, et al
    Relationship between cellular and exosomal miRNAs targeting NOD-like receptors in bladder cancer: preliminary results.
    Minerva Urol Nefrol. 2019 May 28. pii: S0393-2249.19.03297.
    Abstract    

    Abstract available

  5. DUMONT C, Gauthier H, Bonnet C, Culine S, et al
    Understanding chemotherapy-induced changes in bladder cancer biology: a necessary step towards tailored treatment in cisplatin-refractory disease.
    Transl Androl Urol. 2019;8.
    Abstract    



  6. JOSHI M, Warrick JI, Yin M, Holder SL, et al
    Need for a personalized approach for muscle invasive bladder cancer: role of tumor biology in response to neoadjuvant chemotherapy.
    Transl Androl Urol. 2019;8.
    Abstract    



  7. VANDERWEELE DJ, Meeks JJ, Hussain M
    Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?
    Transl Androl Urol. 2019;8.
    Abstract    



  8. LI Q, Zhang P, Wang Y, Zhang Y, et al
    Association between AXIN1 Gene Polymorphisms and Bladder Cancer in Chinese Han Population.
    Dis Markers. 2019;2019:3949343.
    Abstract    

    Abstract available

  9. ZHOU ZF, Fang JB, Chen L, Wang HF, et al
    Effects of intraoperative PEEP on postoperative pulmonary complications in patients undergoing robot-assisted laparoscopic radical resection for bladder cancer or prostate cancer: study protocol for a randomized controlled trial.
    Trials. 2019;20:304.
    Abstract    

    Abstract available

  10. YOSHIDA K, Tsuda M, Matsumoto R, Semba S, et al
    Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer.
    Cancer Sci. 2019 May 29. doi: 10.1111/cas.14080.
    Abstract    

    Abstract available

  11. BUCKWALTER JM, Chan W, Shuman L, Wildermuth T, et al
    Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  12. GARG M, Singh R
    Epithelial-to-mesenchymal transition: Event and core associates in bladder cancer.
    Front Biosci (Elite Ed). 2019;11:150-165.
    Abstract    

    Abstract available

  13. YAN X, Liu XP, Guo ZX, Liu TZ, et al
    Identification of Hub Genes Associated With Progression and Prognosis in Patients With Bladder Cancer.
    Front Genet. 2019;10:408.
    Abstract    

    Abstract available

  14. WANG Y, Chang A, Tan WP, Fantony JJ, et al
    Diet and Exercise Are not Associated with Skeletal Muscle Mass and Sarcopenia in Patients with Bladder Cancer.
    Eur Urol Oncol. 2019 May 25. pii: S2588-9311(19)30061.
    Abstract    

    Abstract available

  15. YUAN W, Zhou R, Wang J, Han J, et al
    Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.
    Mol Oncol. 2019 May 26. doi: 10.1002/1878-0261.12523.
    Abstract    

    Abstract available

  16. CHEN L, Xiong W, Guo W, Su S, et al
    Significance of CLASP2 expression in prognosis for muscle-invasive bladder cancer patients: A propensity score-based analysis.
    Urol Oncol. 2019 May 23. pii: S1078-1439(19)30189.
    Abstract    

    Abstract available

  17. LI Z, Li Y, Wang Y
    miR-19a promotes invasion and epithelial to mesenchymal transition of bladder cancer cells by targeting RhoB.
    J BUON. 2019;24:797-804.
    Abstract    

    Abstract available

  18. LIU X, Zhao W, Wang X, Zhu Y, et al
    Expression of mir-143 in serum of bladder cancer patients and its correlation with clinical features and prognosis.
    J BUON. 2019;24:791-796.
    Abstract    

    Abstract available

  19. LV WL, Liu Q, An JH, Song XY, et al
    Scutellarin inhibits hypoxia-induced epithelial-mesenchymal transition in bladder cancer cells.
    J Cell Physiol. 2019 May 24. doi: 10.1002/jcp.28883.
    Abstract    

    Abstract available

  20. DI MAIDA F, Mari A, Scalici Gesolfo C, Cangemi A, et al
    Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression.
    Clin Genitourin Cancer. 2019 Apr 26. pii: S1558-7673(19)30134.
    Abstract    

    Abstract available

  21. WANG X, Lyu J, Ji A, Zhang Q, et al
    Jarid2 enhances the progression of bladder cancer through regulating PTEN/AKT signaling.
    Life Sci. 2019 May 21. pii: S0024-3205(19)30409.
    Abstract    

    Abstract available

  22. ZHU H, Chen H, Wang J, Zhou L, et al
    Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer.
    Onco Targets Ther. 2019;12:3441-3457.
    Abstract    

    Abstract available

  23. VARUGHESE M, Treece S, Drinkwater KJ
    Radiotherapy Management of Muscle Invasive Bladder Cancer: Evaluation of a National Cohort.
    Clin Oncol (R Coll Radiol). 2019 May 20. pii: S0936-6555(19)30184.
    Abstract    

    Abstract available

  24. SHI G, Liu Q, Chen H, Feng F, et al
    Percutaneous osteoplasty for the management of a humeral head metastasis: Two case reports.
    Medicine (Baltimore). 2019;98:e15727.
    Abstract    

    Abstract available

  25. KOYANAGI Y, Kubo C, Nagata S, Ryu A, et al
    Detection of pagetoid urothelial intraepithelial neoplasia extending to the vagina by cervical screening cytology: a case report with renewed immunochemical summary.
    Diagn Pathol. 2019;14:9.
    Abstract    

    Abstract available

  26. GOFRIT ON, Bercovier H, Klein BY, Cohen IR, et al
    Can immunization with Bacillus Calmette-Guerin (BCG) protect against Alzheimer's disease?
    Med Hypotheses. 2019;123:95-97.
    Abstract    

    Abstract available

  27. ITANO N
    Implications of altered O-glycosylation in tumour immune evasion.
    J Biochem. 2019;165:387-390.
    Abstract    

    Abstract available

  28. FILICE FP, Ding Z
    Analysing single live cells by scanning electrochemical microscopy.
    Analyst. 2019;144:738-752.
    Abstract    

    Abstract available

  29. MATSUURA H, Arase S, Hori Y
    Ureteral stents for malignant extrinsic ureteral obstruction: outcomes and factors predicting stent failure.
    Int J Clin Oncol. 2019;24:306-312.
    Abstract    

    Abstract available

  30. KOO CH, Chung SH, Kim BG, Min BH, et al
    Comparison between the effects of deep and moderate neuromuscular blockade during transurethral resection of bladder tumor on endoscopic surgical condition and recovery profile: a prospective, randomized, and controlled trial.
    World J Urol. 2019;37:359-365.
    Abstract    

    Abstract available

  31. VARTOLOMEI MD, Iwata T, Roth B, Kimura S, et al
    Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis.
    World J Urol. 2019 Jun 6. pii: 10.1007/s00345-019-02825.
    Abstract    

    Abstract available

  32. JACYNA J, Wawrzyniak R, Balayssac S, Gilard V, et al
    Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach.
    Talanta. 2019;202:572-579.
    Abstract    

    Abstract available

  33. RYBICKI F JR, Glanc P
    Patient-Friendly Summary of the ACR Appropriateness Criteria: Pretreatment Staging of Muscle-Invasive Bladder Cancer.
    J Am Coll Radiol. 2019;16:e25.
    Abstract    



  34. LIU L, Wu SQ, Zhu X, Xu R, et al
    Analysis of ceRNA network identifies prognostic circRNA biomarkers in bladder cancer.
    Neoplasma. 2019;2019.
    Abstract    

    Abstract available

  35. LIU L, Wu SQ, Zhu X, Xu R, et al
    Analysis of ceRNA network identifies prognostic circRNA biomarkers in bladder cancer.
    Neoplasma. 2019;2019.
    Abstract    

    Abstract available

  36. JUENGEL E, Natsheh I, Najafi R, Rutz J, et al
    Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro.
    Cancers (Basel). 2019;11.
    Abstract    

    Abstract available

  37. TIAN Z, Luo Y, Zhu J, Hua X, et al
    Transcriptionally elevation of miR-494 by new ChlA-F compound via a HuR/JunB axis inhibits human bladder cancer cell invasion.
    Biochim Biophys Acta Gene Regul Mech. 2019 Jun 2. pii: S1874-9399(19)30018.
    Abstract    

    Abstract available

  38. WILLIAMS SB, Shan Y, Ray-Zack MD, Hudgins HK, et al
    Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer.
    JAMA Surg. 2019 Jun 5:e191629. doi: 10.1001/jamasurg.2019.1629.
    Abstract    

    Abstract available

  39. COLE AP, Trinh QD
    Trimodal Therapy for Bladder Cancer: You Get What You Don't Pay for.
    JAMA Surg. 2019 Jun 5:e191637. doi: 10.1001/jamasurg.2019.1637.
    Abstract    



  40. PAK S, You D, Jeong IG, Song C, et al
    Adjuvant chemotherapy versus observation after radical cystectomy in patients with node-positive bladder cancer.
    Sci Rep. 2019;9:8305.
    Abstract    

    Abstract available

  41. LU BS, Yin YW, Zhang YP, Guo PY, et al
    Upregulation of NPL4 promotes bladder cancer cell proliferation by inhibiting DXO destabilization of cyclin D1 mRNA.
    Cancer Cell Int. 2019;19:149.
    Abstract    

    Abstract available

  42. KORPAL M, Puyang X, Wu ZJ, Seiler R, et al
    Author Correction: Evasion of immunosurveillance by genomic alterations of PPARgamma/RXRalpha in bladder cancer.
    Nat Commun. 2019;10:2527.
    Abstract    

    Abstract available

  43. HUANG J, Lo UG, Wu S, Wang B, et al
    The roles and mechanism of IFIT5 in bladder cancer epithelial-mesenchymal transition and progression.
    Cell Death Dis. 2019;10:437.
    Abstract    

    Abstract available

  44. AYDIN M, Bitkin A, Kadihasanoglu M, Irkilata L, et al
    Correlation of neutrophil-lymphocyte ratio and risk scores in non-muscle invasive bladder cancer.
    Actas Urol Esp. 2019 Jun 1. pii: S0210-4806(19)30073.
    Abstract    

    Abstract available

  45. DUPLISEA JJ, Dinney CPN
    Should chemotherapy still be used to treat all muscle invasive bladder cancer in the "era of immunotherapy"?
    Expert Rev Anticancer Ther. 2019 Jun 5:1-3. doi: 10.1080/14737140.2019.1625773.
    Abstract    



  46. SHIGEMATSU Y, Oue N, Sekino Y, Sakamoto N, et al
    SEC11A Expression Is Associated with Basal-Like Bladder Cancer and Predicts Patient Survival.
    Pathobiology. 2019 Jun 4:1-9. doi: 10.1159/000497206.
    Abstract    

    Abstract available

  47. LI G, Zhang Y, Mao J, Hu P, et al
    lncRNA TUC338 is a potential diagnostic biomarker for bladder cancer.
    J Cell Biochem. 2019 Jun 4. doi: 10.1002/jcb.29104.
    Abstract    

    Abstract available

  48. HERNANDEZ-PRAT A, Rodriguez-Vida A, Juanpere-Rodero N, Arpi O, et al
    Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kalpha inhibitor TAK-117 in preclinical bladder cancer models.
    Mol Cancer Res. 2019 Jun 3. pii: 1541-7786.MCR-18-0923.
    Abstract    

    Abstract available

  49. MAEDA S, Murakami K, Inoue A, Yonezawa T, et al
    CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer.
    Cancer Immunol Res. 2019 Jun 3. pii: 2326-6066.CIR-18-0751.
    Abstract    

    Abstract available

  50. CARNEIRO BDB, Sanches BCF, Andrade DL, Voris BRI, et al
    Moreau Strain Bacillus Calmette-Guerin Low Versus Standard Dose in the Treatment of High-Grade T1 Bladder Cancer: A Retrospective Observational Cohort Study.
    Clin Genitourin Cancer. 2019 Apr 16. pii: S1558-7673(19)30129.
    Abstract    

    Abstract available

  51. BLINOVA E, Roshchin D, Kogan E, Samishina E, et al
    Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment.
    Cells. 2019;8.
    Abstract    

    Abstract available

  52. TRENTI E, D'Elia C, Mian C, Schwienbacher C, et al
    Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
    Cancer Cytopathol. 2019 Jun 2. doi: 10.1002/cncy.22152.
    Abstract    

    Abstract available

  53. BOCHENEK K, Aebisher D, Miedzybrodzka A, Cieslar G, et al
    Methods of bladder cancer diagnostics - the role of autofluorescence and photodynamic diagnosis.
    Photodiagnosis Photodyn Ther. 2019 May 29. pii: S1572-1000(19)30126.
    Abstract    

    Abstract available

  54. THUENER JE
    Urologic Malignancies.
    Prim Care. 2019;46:275-285.
    Abstract    

    Abstract available

  55. HOLLAND BC, Sood A, Delfino K, Dynda DI, et al
    Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
    Cancer Immunol Immunother. 2019;68:991-997.
    Abstract    

    Abstract available

  56. TSUI KH, Hou CP, Chang KS, Lin YH, et al
    Metallothionein 3 Is a Hypoxia-Upregulated Oncogene Enhancing Cell Invasion and Tumorigenesis in Human Bladder Carcinoma Cells.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  57. TSE J, Ghandour R, Singla N, Lotan Y, et al
    Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  58. LAMBERT E, D'Hondt F, Mazzone E, Vollemaere J, et al
    Time to Move On: The Impending Need for a New Disease-specific Comorbidity Index for Bladder Cancer Patients Undergoing Robot-assisted Radical Cystectomy.
    Eur Urol Focus. 2019 Jun 11. pii: S2405-4569(19)30152.
    Abstract    

    Abstract available

  59. WEINER AB, Desai AS, Meeks JJ
    Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study.
    Eur Urol Oncol. 2019;2:304-310.
    Abstract    

    Abstract available

  60. RUAN JL, Hsu JW, Browning RJ, Stride E, et al
    Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes.
    Eur Urol Oncol. 2019;2:239-247.
    Abstract    

    Abstract available

  61. MAN X, Piao C, Lin X, Kong C, et al
    USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer.
    J Exp Clin Cancer Res. 2019;38:259.
    Abstract    

    Abstract available

  62. HAU AM, Gupta S, Leivo MZ, Nakashima K, et al
    Dynamic Regulation of Caveolin-1 Phosphorylation and Caveolae Formation by mTORC2 in Bladder Cancer Cells.
    Am J Pathol. 2019 Jun 11. pii: S0002-9440(19)30079.
    Abstract    

    Abstract available

  63. YAMADA Y, Kato M, Arai T, Sanada H, et al
    Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target.
    Mol Oncol. 2019 Jun 14. doi: 10.1002/1878-0261.12532.
    Abstract    

    Abstract available

  64. LIU X, Wu Y, Zhou Z, Huang M, et al
    Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis.
    Int J Mol Med. 2019 Jun 12. doi: 10.3892/ijmm.2019.4241.
    Abstract    

    Abstract available

  65. SONG YP, McWilliam A, Hoskin PJ, Choudhury A, et al
    Organ preservation in bladder cancer: an opportunity for truly personalized treatment.
    Nat Rev Urol. 2019 Jun 13. pii: 10.1038/s41585-019-0199.
    Abstract    

    Abstract available

  66. ZHANG P, Zhang Y, Liu W, Cui D, et al
    A Molecular Beacon Based Surface-Enhanced Raman Scattering Nanotag for Noninvasive Diagnosis of Bladder Cancer.
    J Biomed Nanotechnol. 2019;15:1589-1597.
    Abstract    

    Abstract available

  67. QIN MM, Chai X, Huang HB, Feng G, et al
    let-7i inhibits proliferation and migration of bladder cancer cells by targeting HMGA1.
    BMC Urol. 2019;19:53.
    Abstract    

    Abstract available

  68. GRUNEWALD CM, Niegisch G
    [Personalised medicine in urothelial bladder cancer].
    Aktuelle Urol. 2019 Jun 13. doi: 10.1055/a-0927-6725.
    Abstract    

    Abstract available

  69. ISLAM MO, Bacchetti T, Ferretti G
    Alterations of Antioxidant Enzymes and Biomarkers of Nitro-oxidative Stress in Tissues of Bladder Cancer.
    Oxid Med Cell Longev. 2019;2019:2730896.
    Abstract    

    Abstract available

  70. YANG Y, Zhang G, Li C, Wang S, et al
    Metabolic profile and structure-activity relationship of resveratrol and its analogs in human bladder cancer cells.
    Cancer Manag Res. 2019;11:4631-4642.
    Abstract    

    Abstract available

  71. WANG SS, Chen G, Li SH, Pang JS, et al
    Identification and validation of an individualized autophagy-clinical prognostic index in bladder cancer patients.
    Onco Targets Ther. 2019;12:3695-3712.
    Abstract    

    Abstract available

  72. CAO Z, Xu L, Zhao S, Zhu X, et al
    The functions of microRNA-124 on bladder cancer.
    Onco Targets Ther. 2019;12:3429-3439.
    Abstract    

    Abstract available

  73. XU N, Qu GY, Wu YP, Lin YZ, et al
    ARPC4 promotes bladder cancer cell invasion and is associated with lymph node metastasis.
    J Cell Biochem. 2019 Jun 12. doi: 10.1002/jcb.29136.
    Abstract    

    Abstract available

  74. STEWART TF, Petrylak DP
    Atezolizumab in understudied populations with bladder cancer.
    Nat Rev Urol. 2019 Jun 11. pii: 10.1038/s41585-019-0200.
    Abstract    



  75. XIONG YQ, Tan J, Liu YM, Li YZ, et al
    Diagnostic accuracy of optical coherence tomography for the diagnosis of bladder cancer: A systematic review and meta-analysis.
    Photodiagnosis Photodyn Ther. 2019 Jun 8. pii: S1572-1000(19)30134.
    Abstract    

    Abstract available

  76. KOUHSAR M, Azimzadeh Jamalkandi S, Moeini A, Masoudi-Nejad A, et al
    Detection of novel biomarkers for early detection of Non-Muscle-Invasive Bladder Cancer using Competing Endogenous RNA network analysis.
    Sci Rep. 2019;9:8434.
    Abstract    

    Abstract available

  77. QIU J, Zeng FR, Fang Y, Li J, et al
    Increased miR-323a induces bladder cancer cell apoptosis by suppressing c-Met.
    Kaohsiung J Med Sci. 2019 Jun 10. doi: 10.1002/kjm2.12091.
    Abstract    

    Abstract available

  78. CAO Z, Peng L, He K, Wang X, et al
    Value of quantitative and qualitative analyses of serum and urine cell-free DNA as diagnostic tools for bladder cancer: a meta-analysis.
    Expert Rev Anticancer Ther. 2019 Jun 10. doi: 10.1080/14737140.2019.1626723.
    Abstract    

    Abstract available

  79. SELL V, Ettala O, Montoya Perez I, Jarvinen R, et al
    Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial.
    World J Urol. 2019 Jun 8. pii: 10.1007/s00345-019-02841.
    Abstract    

    Abstract available

  80. MAO W, Luo M, Huang X, Wang Q, et al
    Knockdown of Lumican Inhibits Proliferation and Migration of Bladder Cancer.
    Transl Oncol. 2019;12:1072-1078.
    Abstract    

    Abstract available

  81. LIU X, Jiang J, Yu C, Wang Y, et al
    Secular trends in incidence and mortality of bladder cancer in China, 1990-2017: A joinpoint and age-period-cohort analysis.
    Cancer Epidemiol. 2019;61:95-103.
    Abstract    

    Abstract available

  82. MA QY, Li SY, Li XZ, Zhou TF, et al
    Long non-coding RNA DILC suppresses bladder cancer cells progression.
    Gene. 2019;710:193-201.
    Abstract    

    Abstract available

  83. SCHULZ GB, Grimm T, Sers C, Riemer P, et al
    Prognostic value and association with epithelial-mesenchymal transition and molecular subtypes of the proteoglycan biglycan in advanced bladder cancer.
    Urol Oncol. 2019 Jun 5. pii: S1078-1439(19)30197.
    Abstract    

    Abstract available

  84. MOHAMED N, Leung TM, Shah QN, Pisipati S, et al
    Involving Patients in the Development and Evaluation of an Educational and Training Experiential Intervention (ETEI) to Improve Muscle Invasive Bladder Cancer Treatment Decision-making and Post-operative Self-care: a Mixed Methods Approach.
    J Cancer Educ. 2019 Jun 7. pii: 10.1007/s13187-019-01534.
    Abstract    

    Abstract available

  85. SCHULZ GB, Schlenker B, Stief CG
    [Aftercare of non-muscle invasive bladder cancer].
    Urologe A. 2019 Jun 7. pii: 10.1007/s00120-019-0956.
    Abstract    

    Abstract available

  86. VIDOTTO T, Nersesian S, Graham C, Siemens DR, et al
    DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.
    J Immunother Cancer. 2019;7:148.
    Abstract    

    Abstract available

  87. RUSSELL B, Sherif A, Haggstrom C, Josephs D, et al
    Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival.
    Scand J Urol. 2019 Jun 7:1-7. doi: 10.1080/21681805.2019.1624611.
    Abstract    

    Abstract available

  88. NIELSEN N, Wrist Lam G, Fabrin K, Holt P, et al
    Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
    Scand J Urol. 2019 Jun 7:1-4. doi: 10.1080/21681805.2019.1624608.
    Abstract    

    Abstract available

  89. LEE YC, Kurtova AV, Xiao J, Nikolos F, et al
    Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung.
    Nat Commun. 2019;10:2131.
    Abstract    

    Abstract available

  90. JIAO J, Wang W, Guang H, Lin H, et al
    2,4,5-Trichloro-6-((2,4,6-trichlorophenyl)amino)isophthalonitrile, Exerts Anti-bladder Activities through IGF-1R/STAT3 Signaling.
    Chem Pharm Bull (Tokyo). 2019;67:410-418.
    Abstract    

    Abstract available

  91. KANG H, Kim DH, Lee W, Ha J, et al
    First Case of Cellular Cannibalism in Small-Cell Carcinoma of the Bladder Detected in Peripheral Blood.
    Ann Lab Med. 2019;39:400-402.
    Abstract    



  92. SU H, Tao T, Yang Z, Kang X, et al
    Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression.
    Mol Cancer. 2019;18:27.
    Abstract    

    Abstract available

  93. GHALLEB M, Ayadi MA, Slim S, Zemni I, et al
    Multiple cutaneous metastasis of synchronous urothelial carcinoma of the bladder and the renal pelvis: a case report.
    J Med Case Rep. 2019;13:34.
    Abstract    

    Abstract available

  94. TSUBOI M, Sakai K, Maeda S, Chambers JK, et al
    Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder.
    Vet Pathol. 2019;56:369-376.
    Abstract    

    Abstract available

  95. WANG J, Wang G, Shan H, Wang X, et al
    Gradiently degraded electrospun polyester scaffolds with cytostatic for urothelial carcinoma therapy.
    Biomater Sci. 2019;7:963-974.
    Abstract    

    Abstract available

  96. SANGUEDOLCE F, Russo D, Mancini V, Selvaggio O, et al
    Morphological and Immunohistochemical Biomarkers in Distinguishing Prostate Carcinoma and Urothelial Carcinoma: A Comprehensive Review.
    Int J Surg Pathol. 2019;27:120-133.
    Abstract    

    Abstract available

  97. LUO J, Lou Z, Zheng J
    Targeted regulation by ROCK2 on bladder carcinoma via Wnt signaling under hypoxia.
    Cancer Biomark. 2019;24:109-116.
    Abstract    

    Abstract available

  98. NOMURA M, Matsumoto K, Shimizu Y, Ikeda M, et al
    TROY expression is associated with pathological stage and poor prognosis in patients treated with radical cystectomy.
    Cancer Biomark. 2019;24:91-96.
    Abstract    

    Abstract available

  99. VASDEV N, Zargar H, Noel JP, Veeratterapillay R, et al
    Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.
    World J Urol. 2019;37:165-172.
    Abstract    

    Abstract available

  100. BHANVADIA S, Kazerouni K, Bazargani ST, Miranda G, et al
    Validating the role of ABO blood type in risk of perioperative venous thromboembolism after radical cystectomy.
    World J Urol. 2019;37:173-179.
    Abstract    

    Abstract available

  101. LI J, Huang C, Xiong T, Zhuang C, et al
    A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells In Vitro.
    Int J Biol Sci. 2019;15:1276-1286.
    Abstract    

    Abstract available

  102. KOUZNETSOVA VL, Kim E, Romm EL, Zhu A, et al
    Recognition of early and late stages of bladder cancer using metabolites and machine learning.
    Metabolomics. 2019;15:94.
    Abstract    

    Abstract available

  103. LUO Y, Tian Z, Hua X, Huang M, et al
    Isorhapontigenin (ISO) inhibits stem cell-like properties and invasion of bladder cancer cell by attenuating CD44 expression.
    Cell Mol Life Sci. 2019 Jun 20. pii: 10.1007/s00018-019-03185.
    Abstract    

    Abstract available

  104. LI F, Zhao H, Su M, Xie W, et al
    HnRNP-F regulates EMT in bladder cancer by mediating the stabilization of Snail1 mRNA by binding to its 3' UTR.
    EBioMedicine. 2019 Jun 17. pii: S2352-3964(19)30398.
    Abstract    

    Abstract available

  105. DAVIDSON PJ, McGeoch G, Shand B
    Inclusion of a molecular marker of bladder cancer in a clinical pathway for investigation of haematuria may reduce the need for cystoscopy.
    N Z Med J. 2019;132:55-64.
    Abstract    

    Abstract available

  106. COBAN N, Varol N
    The effect of heat shock protein 90 inhibitors on histone 4 lysine 20 methylation in bladder cancer.
    EXCLI J. 2019;18:195-203.
    Abstract    

    Abstract available

  107. JIA LH, Hu MD, Liu Y, Xiong X, et al
    HSDL2 Promotes Bladder Cancer Growth In Vitro and In Vivo.
    Int J Med Sci. 2019;16:654-659.
    Abstract    

    Abstract available

  108. GUO H, Hou Y, Ding J
    Nanomedicines for Intravesical Chemotherapy in Bladder Cancer.
    Curr Pharm Des. 2019;25:371-373.
    Abstract    



  109. RYDER REJ, DeFronzo RA
    Pioglitazone: inexpensive; very effective at reducing HbA1c ; no evidence of bladder cancer risk; plenty of evidence of cardiovascular benefit.
    Diabet Med. 2019 Jun 18. doi: 10.1111/dme.14053.
    Abstract    

    Abstract available

  110. SETTI BOUBAKER N, Cicchillitti L, Said R, Gurtner A, et al
    The clinical and prognostic value of miR-9 gene expression in Tunisian patients with bladder cancer.
    Mol Biol Rep. 2019 Jun 18. pii: 10.1007/s11033-019-04920.
    Abstract    

    Abstract available

  111. CALO B, Chirico M, Fortunato F, Sanguedolce F, et al
    Is Repeat Transurethral Resection Always Needed in High-Grade T1 Bladder Cancer?
    Front Oncol. 2019;9:465.
    Abstract    

    Abstract available

  112. MASON SJ, Downing A, Wright P, Bottomley SE, et al
    Life and bladder cancer: protocol for a longitudinal and cross-sectional patient-reported outcomes study of Yorkshire (UK) patients.
    BMJ Open. 2019;9:e030850.
    Abstract    

    Abstract available

  113. LI G, Wang M, Ren L, Li H, et al
    Regulator of G protein signaling 20 promotes proliferation and migration in bladder cancer via NF-kappaB signaling.
    Biomed Pharmacother. 2019;117:109112.
    Abstract    

    Abstract available

  114. ANDO T, Watanabe K, Nakayama R, Mizusawa T, et al
    Trousseau's syndrome manifesting as multiple cerebral infarctions caused by bladder cancer.
    Urol Case Rep. 2019;24:100884.
    Abstract    

    Abstract available

  115. DENSMORE R, Hajizadeh M, Hu M
    Trends in socio-economic inequalities in bladder cancer incidence in Canada: 1992-2010.
    Can J Public Health. 2019 Jun 17. pii: 10.17269/s41997-019-00227.
    Abstract    

    Abstract available

  116. ACHAM M, Wesselius A, van Osch FHM, Yu EY, et al
    Intake of milk and other dairy products and the risk of bladder cancer: a pooled analysis of 13 cohort studies.
    Eur J Clin Nutr. 2019 Jun 17. pii: 10.1038/s41430-019-0453.
    Abstract    

    Abstract available

  117. ANGELE CM, Alessandra C, Martina D, Margherita G, et al
    Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells.
    Free Radic Biol Med. 2019 Jun 14. pii: S0891-5849(18)32523.
    Abstract    

    Abstract available

  118. MASAOKA H, Matsuo K, Oze I, Ito H, et al
    Alcohol drinking and bladder cancer risk from a pooled analysis of ten cohort studies in Japan.
    J Epidemiol. 2019 Jun 15. doi: 10.2188/jea.JE20190014.
    Abstract    

    Abstract available

  119. LUO Y, Barrios-Rodiles M, Gupta GD, Zhang YY, et al
    Atypical function of a centrosomal module in WNT signalling drives contextual cancer cell motility.
    Nat Commun. 2019;10:2356.
    Abstract    

    Abstract available

  120. PIETILA M, Sahgal P, Peuhu E, Jantti NZ, et al
    SORLA regulates endosomal trafficking and oncogenic fitness of HER2.
    Nat Commun. 2019;10:2340.
    Abstract    

    Abstract available

  121. WEI Y, Wang M, Liu H, Niu Y, et al
    Simultaneous determination of seven endogenous aldehydes in human blood by headspace gas chromatography-mass spectrometry.
    J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1118-1119:85-92.
    Abstract    

    Abstract available

  122. HURST EA, Pang LY, Argyle DJ
    The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels.
    Vet Comp Oncol. 2019;17:194-207.
    Abstract    

    Abstract available

  123. MAO S, Zhang J, Guo Y, Zhang Z, et al
    Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.
    Drug Des Devel Ther. 2019;13:291-300.
    Abstract    

    Abstract available

  124. MARTINI A, Jia R, Ferket BS, Waingankar N, et al
    Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.
    Cancer. 2019 May 31. doi: 10.1002/cncr.32169.
    Abstract    

    Abstract available

  125. SATYAL U, Sikder RK, McConkey D, Plimack ER, et al
    Clinical implications of molecular subtyping in bladder cancer.
    Curr Opin Urol. 2019;29:350-356.
    Abstract    

    Abstract available

  126. LI R, Tabayoyong WB, Guo CC, Gonzalez GMN, et al
    Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.
    Eur Urol. 2019;75:8-10.
    Abstract    

    Abstract available

  127. FICARRA V, Giannarini G, Crestani A, Palumbo V, et al
    Retrosigmoid Versus Traditional Ileal Conduit for Urinary Diversion After Radical Cystectomy.
    Eur Urol. 2019;75:294-299.
    Abstract    

    Abstract available

  128. NAMEKAWA T, Ikeda K, Horie-Inoue K, Suzuki T, et al
    ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression.
    Int J Cancer. 2019 Jun 12. doi: 10.1002/ijc.32505.
    Abstract    

    Abstract available

  129. YANG J, Zhang P, Zhou H, Feng S, et al
    Prospective, randomized controlled study of the preventive effect of fosfomycin tromethamine on post-transurethral resection of bladder tumor urinary tract infection.
    Int J Urol. 2018 Jul 12. doi: 10.1111/iju.13719.
    Abstract    



  130. TSENG WH, Liu CL, Huang SK, Liao AC, et al
    Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience.
    Int Urol Nephrol. 2019 May 25. pii: 10.1007/s11255-019-02172.
    Abstract    

    Abstract available

  131. SLUSARCZYK A, Zapala P, Zapala L, Piecha T, et al
    Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics.
    Int Urol Nephrol. 2019 Jun 1. pii: 10.1007/s11255-019-02183.
    Abstract    

    Abstract available

  132. WU S, Lin SX, Lu M, Subtelny AO, et al
    Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy.
    Int Urol Nephrol. 2019 Jun 10. pii: 10.1007/s11255-019-02181.
    Abstract    

    Abstract available

  133. WU J, Wang YC, Dai B, Ye DW, et al
    Optical biopsy of bladder cancer using confocal laser endomicroscopy.
    Int Urol Nephrol. 2019 Jun 13. pii: 10.1007/s11255-019-02197.
    Abstract    

    Abstract available

  134. WESTERGREN DO, Gardmark T, Lindhagen L, Chau A, et al
    A Nationwide Population Based Analysis of Organ-Confined Muscle-Invasive Bladder Cancer Patients Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014.
    J Urol. 2019 May 30:101097JU0000000000000350. doi: 10.1097/JU.0000000000000350.
    Abstract    

    Abstract available

  135. METCALF M, Glazyrine V, Glavin K, Dahlgren A, et al
    The Feasibility of a Health Care Application in the Treatment of Patients Undergoing Radical Cystectomy.
    J Urol. 2019;201:902-908.
    Abstract    

    Abstract available

  136. ROTH B, Furrer MA, Giannakis I, Vartolomei MD, et al
    Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution.
    J Urol. 2019;201:909-915.
    Abstract    

    Abstract available

  137. RAVVAZ K, Weissert JA, Downs TM
    American Urological Association Non-muscle Invasive Bladder Cancer Risk Model Validation: Should patient age be added to the risk model?
    J Urol. 2019 Jun 12:101097JU0000000000000389. doi: 10.1097/JU.0000000000000389.
    Abstract    

    Abstract available

  138. CHANG SS
    Re: Predicting Grade and Stage at Cystoscopy in Newly Presenting Bladder Cancers-A Prospective Double-Blind Clinical Study.
    J Urol. 2019 Jun 10:10109701JU00005691889046242.
    Abstract    



  139. CHANG SS
    Re: Disseminated Mycobacterium bovis Infection Post-Kidney Transplant following Remote Intravesical BCG Therapy for Bladder Cancer.
    J Urol. 2019 Jun 10:101097JU0000000000000381. doi: 10.1097/JU.0000000000000381.
    Abstract    



  140. FILIPPOU P, Smith AB
    Editorial Comment.
    J Urol. 2019;202:89.
    Abstract    



  141. SUN X, Song J, Li E, Geng H, et al
    ()Epigallocatechin3gallate inhibits bladder cancer stem cells via suppression of sonic hedgehog pathway.
    Oncol Rep. 2019 May 24. doi: 10.3892/or.2019.7170.
    Abstract    

    Abstract available

  142. POINAS G, Blache JL, Kassab-Chahmi D, Evrard PL, et al
    [Short version of recommendations for enhanced recovery program (ERP) for cystectomy: Technical measures].
    Prog Urol. 2019;29:63-75.
    Abstract    

    Abstract available

  143. MOUDOUNI SM, Latabi AF, Aarab M, Lakmichi MA, et al
    [Oncological results of a series of 93 laparoscopic radical cystectomies: 5 years of follow-up].
    Prog Urol. 2019;29:86-94.
    Abstract    

    Abstract available

  144. BI H, Huang Y, Wang G, Ma L, et al
    Impact of Body Mass Index and Pretreatment Hemoglobin Level on Prognosis Following Radical Cystectomy for Bladder Cancer in Males and Females.
    Urol Int. 2019 Jun 18:1-8. doi: 10.1159/000500561.
    Abstract    

    Abstract available

  145. HAN DS, Lynch KE, Chang JW, Sirovich B, et al
    Overuse of Cystoscopic Surveillance among Patients with Low-Risk Non-Muscle-Invasive Bladder Cancer - A National Study of Patient, Provider, and Facility Factors.
    Urology. 2019 May 27. pii: S0090-4295(19)30448.
    Abstract    

    Abstract available

  146. DANFORTH KN, Sidell MA, Luong TQ, Yi DK, et al
    Care Quality and Variability in the Use of Intravesical Therapy for Initial Treatment of Non-Muscle Invasive Bladder Cancer within a Large, Diverse Integrated Delivery System.
    Urology. 2019 May 24. pii: S0090-4295(19)30442.
    Abstract    

    Abstract available

  147. MAY D, Canter DJ
    EDITORIAL COMMENT.
    Urology. 2019;125:228-229.
    Abstract    



  148. GILBERT SM
    EDITORIAL COMMENT.
    Urology. 2019;125:152-153.
    Abstract    



  149. PEREIRA JF, Pareek G, Mueller-Leonhard C, Zhang Z, et al
    The Perioperative Morbidity of Transurethral Resection of Bladder Tumor: Implications for Quality Improvement.
    Urology. 2019;125:131-137.
    Abstract    

    Abstract available

  150. MODI PK, Hollenbeck BK, Oerline M, Weizer AZ, et al
    Real-World Impact of Minimally Invasive Versus Open Radical Cystectomy on Perioperative Outcomes and Spending.
    Urology. 2019;125:86-91.
    Abstract    

    Abstract available

  151. PATEL KR, Taylor BL, Khani F, Guzzo TJ, et al
    Impact of Neoadjuvant Chemotherapy on Concordance of PD-L1 Staining Fidelity between the Primary Tumor and Lymph Node Metastases in Bladder Cancer.
    Urology. 2019 Jun 12. pii: S0090-4295(19)30528.
    Abstract    

    Abstract available

  152. CORBETT CJ, Xia L, Mamtani R, Malkowicz SB, et al
    Survival Benefit Persists with Delayed Initiation of Adjuvant Chemotherapy following Radical Cystectomy for Locally Advanced Bladder Cancer.
    Urology. 2019 Jun 11. pii: S0090-4295(19)30522.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;